With growing interest in the role of modern pharmaceutics in early stage of drug discovery and development, rationale design of drug delivery systems for poorly soluble drugs has been widely explored, such as emulsions [3, 4], solid lipid nanoparticles [5, 6], micelles, and liposomes [7, 8].
This chapter sheds light on the latter discovery and provides a rationale for follow-up questions, such as the nature of interaction between Piezo1 and Piezo2, and their tethering to the cytoskeleton.
In recent years, structure-based virtual design and the three-dimensional structure of a drug-target interaction with small molecular weight inhibitors has been used to guide rationale drug discovery [41].
Such information may increase our understanding of the disease process, guide future drug discovery or provide a rationale for the use of particular drugs in particular diseases.
Alternatively, in silico approaches in which compounds are docked to the structures of predicted targets have also been used in lieu of biochemical screening to generate rationale drug discovery leads.
The rationale of discovery-based high-throughput investigation of disease is that there are molecular signatures (composed of genes, transcripts, proteins, and small molecules) that can be identified for better diagnosis, prognosis, and/or treatment of disease.
These compounds, as well as the underlying design rationale, may find usefulness in the discovery and development of new antimalarial drugs.
Big Data research and discovery is built upon solid rationale, fundamental knowledge, and deep thinking of scientists and scholars.
Furthermore, cancer-associated aberrations in glycan structures provide a compelling rationale for the discovery of new biomarkers through the isolation and identification of glycoproteins that contain these glycan structures.
A recent paper has described the rationale for and discovery of a new class of drugs - transcriptional noise enhancers - that can synergize with conventional transcription activators to more effectively reactivate latently infected T cells.
